Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NVGN's Cash-to-Debt is ranked higher than
98% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. NVGN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NVGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.92  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.70
NVGN's Equity-to-Asset is ranked higher than
64% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NVGN: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
NVGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.72 Max: 0.97
Current: 0.7
0.32
0.97
Interest Coverage No Debt
NVGN's Interest Coverage is ranked higher than
98% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. NVGN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NVGN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 9.75
Beneish M-Score: 0.73
WACC vs ROIC
10.81%
-228.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3455.64
NVGN's Operating Margin % is ranked lower than
98% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.38 vs. NVGN: -3455.64 )
Ranked among companies with meaningful Operating Margin % only.
NVGN' s Operating Margin % Range Over the Past 10 Years
Min: -9158.43  Med: -245.36 Max: -156.04
Current: -3455.64
-9158.43
-156.04
Net Margin % -3257.48
NVGN's Net Margin % is ranked lower than
97% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. NVGN: -3257.48 )
Ranked among companies with meaningful Net Margin % only.
NVGN' s Net Margin % Range Over the Past 10 Years
Min: -8583.91  Med: -245.35 Max: 90.46
Current: -3257.48
-8583.91
90.46
ROE % -34.77
NVGN's ROE % is ranked lower than
87% of the 598 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.12 vs. NVGN: -34.77 )
Ranked among companies with meaningful ROE % only.
NVGN' s ROE % Range Over the Past 10 Years
Min: -269.02  Med: -52.48 Max: 33.98
Current: -34.77
-269.02
33.98
ROA % -30.12
NVGN's ROA % is ranked lower than
88% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. NVGN: -30.12 )
Ranked among companies with meaningful ROA % only.
NVGN' s ROA % Range Over the Past 10 Years
Min: -143.49  Med: -39.8 Max: 12.06
Current: -30.12
-143.49
12.06
ROC (Joel Greenblatt) % -513.86
NVGN's ROC (Joel Greenblatt) % is ranked lower than
90% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.08 vs. NVGN: -513.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14620.2  Med: -1731.46 Max: -348.56
Current: -513.86
-14620.2
-348.56
3-Year Revenue Growth Rate -53.60
NVGN's 3-Year Revenue Growth Rate is ranked lower than
97% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NVGN: -53.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -19.3 Max: 5.3
Current: -53.6
-100
5.3
3-Year EBITDA Growth Rate 44.20
NVGN's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. NVGN: 44.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.1  Med: -7.8 Max: 44.2
Current: 44.2
-61.1
44.2
3-Year EPS without NRI Growth Rate 29.10
NVGN's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. NVGN: 29.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8  Med: -8.2 Max: 29.1
Current: 29.1
-57.8
29.1
GuruFocus has detected 6 Warning Signs with Novogen Ltd $NVGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVGN's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVGN Guru Trades in Q1 2016

Jim Simons 137,300 sh (-1.29%)
» More
Q2 2016

NVGN Guru Trades in Q2 2016

Jim Simons 137,300 sh (unchged)
» More
Q3 2016

NVGN Guru Trades in Q3 2016

Jim Simons 137,300 sh (unchged)
» More
Q4 2016

NVGN Guru Trades in Q4 2016

Jim Simons 137,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:AMEX:AXN, NAS:PRPH, NAS:IMNP, OTCPK:CHEXF, OTCPK:SUWN, NAS:TNXP, OTCPK:INNV, NAS:ALQA, AMEX:CPHI, NAS:BSPM, OTCPK:INBP, OTCPK:PXSLY, OTCPK:ECTE, OTCPK:ENZB, AMEX:NNVC, OTCPK:BIOYF, NAS:ALIM, NAS:OASM, NAS:ZGNX, NAS:RMTI » details
Traded in other countries:NRT.Australia, NV9B.Germany, NVGNF.USA,
Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure.

Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 1.15
NVGN's PB Ratio is ranked higher than
85% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. NVGN: 1.15 )
Ranked among companies with meaningful PB Ratio only.
NVGN' s PB Ratio Range Over the Past 10 Years
Min: 0.34  Med: 3.66 Max: 45.56
Current: 1.15
0.34
45.56
Current Ratio 9.80
NVGN's Current Ratio is ranked higher than
94% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. NVGN: 9.80 )
Ranked among companies with meaningful Current Ratio only.
NVGN' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 6.49 Max: 27.14
Current: 9.8
0.81
27.14
Quick Ratio 9.80
NVGN's Quick Ratio is ranked higher than
95% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVGN: 9.80 )
Ranked among companies with meaningful Quick Ratio only.
NVGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 5.52 Max: 27.14
Current: 9.8
0.81
27.14
Days Sales Outstanding 363.08
NVGN's Days Sales Outstanding is ranked lower than
98% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. NVGN: 363.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.51  Med: 52.34 Max: 435.3
Current: 363.08
1.51
435.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -45.50
NVGN's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. NVGN: -45.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -72.4  Med: -4.1 Max: 40.6
Current: -45.5
-72.4
40.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.91
NVGN's Price-to-Net-Cash is ranked higher than
65% of the 136 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.43 vs. NVGN: 7.91 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NVGN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.78  Med: 4.92 Max: 23.09
Current: 7.91
0.78
23.09
Price-to-Net-Current-Asset-Value 4.05
NVGN's Price-to-Net-Current-Asset-Value is ranked higher than
74% of the 337 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. NVGN: 4.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.46  Med: 3.75 Max: 19
Current: 4.05
0.46
19
Price-to-Tangible-Book 2.68
NVGN's Price-to-Tangible-Book is ranked higher than
56% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NVGN: 2.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.45  Med: 3.65 Max: 160
Current: 2.68
0.45
160
Price-to-Median-PS-Value 7.91
NVGN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.22 vs. NVGN: 7.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.08 Max: 14
Current: 7.91
0
14
Earnings Yield (Greenblatt) % -49.87
NVGN's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NVGN: -49.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -42856.76  Med: 0 Max: 10768.64
Current: -49.87
-42856.76
10768.64

More Statistics

Revenue (TTM) (Mil) $0.28
EPS (TTM) $ -0.53
Beta0.90
Short Percentage of Float0.03%
52-Week Range $1.39 - 2.85
Shares Outstanding (Mil)19.33

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 4 4
EPS ($) -0.89 -1.41 -0.05
EPS without NRI ($) -0.89 -1.41 -0.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)